Cargando…

Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients

BACKGROUND: The treatment of choice for advanced non–small cell lung cancer is selected according to the presence of specific alterations. Patients should undergo molecular testing for relevant modifications and the mutational status of EGFR and translocation of ALK and ROS1 are commonly tested to o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schluckebier, Luciene, Caetano, Rosangela, Garay, Osvaldo Ulises, Montenegro, Giuliana T., Custodio, Marcelo, Aran, Veronica, Gil Ferreira, Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489015/ https://www.ncbi.nlm.nih.gov/pubmed/32928143 http://dx.doi.org/10.1186/s12885-020-07240-2

Ejemplares similares

Comparison between Immunocytochemistry, FISH and NGS for ALK and ROS1 Rearrangement Detection in Cytological Samples
por: Frankel, Diane, et al.
Publicado: (2022)

ALK and ROS1 concurrent with EGFR mutation in patients with lung adenocarcinoma
por: Mao, Yanjiao, et al.
Publicado: (2017)

Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS
por: Korpanty, Grzegorz J., et al.
Publicado: (2014)

Clinicopathological characteristics with EGFR, ALK, ROS1 genetic alternation and prognostic analysis of primary lymphoepithelioma-like carcinoma
por: Shen, Yinchen, et al.
Publicado: (2019)

Clinical characteristics of non‐small cell lung cancer patients with EGFR mutations and ALK&ROS1 fusions
por: Liu, Qinghua, et al.
Publicado: (2022)

Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements
por: Wu, Shafei, et al.
Publicado: (2015)

Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options
por: Desai, Arpita, et al.
Publicado: (2016)

EGFR mutations and ROS1 and ALK rearrangements in a large series of non‐small cell lung cancer in South India
por: Tarigopula, Anil, et al.
Publicado: (2020)

Current Advances in Nanotechnology for the Next Generation of Sequencing (NGS)
por: Bracamonte, Angel Guillermo
Publicado: (2023)

Overview of ALK and ROS1 Rearranged Lung Cancer
por: Choi, Chang Min
Publicado: (2013)

PD‐L1 expression in ROS1‐rearranged non‐small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1
por: Lee, Jongmin, et al.
Publicado: (2018)

Evaluating next‐generation sequencing (NGS) methods for routine monitoring of wild bees: Metabarcoding, mitogenomics or NGS barcoding
por: Gueuning, Morgan, et al.
Publicado: (2019)

Detecting EGFR mutations and ALK/ROS1 rearrangements in non‐small cell lung cancer using malignant pleural effusion samples
por: Yao, Yi, et al.
Publicado: (2018)

Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations
por: Wang, H.-Y., et al.
Publicado: (2022)

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations
por: Lou, Na-Na, et al.
Publicado: (2016)

Next generation sequencing (NGS) strategies for the genetic testing of myopathies
por: NIGRO, VINCENZO, et al.
Publicado: (2012)

NGS-Trex: Next Generation Sequencing Transcriptome profile explorer
por: Boria, Ilenia, et al.
Publicado: (2013)

GAM-NGS: genomic assemblies merger for next generation sequencing
por: Vicedomini, Riccardo, et al.
Publicado: (2013)

Initiative for standardization of the format of the next-generation sequencing (NGS) results
por: Pipan, Veronika, et al.
Publicado: (2015)

Editorial: Next Generation Sequencing (NGS) for Rare Diseases Diagnosis
por: Yang, Xiu-An
Publicado: (2021)

Editorial: Application of Next Generation Sequencing (NGS) in Infection Prevention
por: Kemp, Michael, et al.
Publicado: (2022)

P1006: NEXT GENERATION SEQUENCING (NGS) IN PEDIATRIC MASTOCYTOSIS
por: Angi, A., et al.
Publicado: (2022)

Next Generation Sequencing (NGS) Target Approach for Undiagnosed Dysglycaemia
por: Aloi, Concetta, et al.
Publicado: (2023)

NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF-β receptor blocker galunisertib in HCC
por: Cao, Yuan, et al.
Publicado: (2017)

Reactive Oxygen Species (ROS): Beneficial Companions of Plants’ Developmental Processes
por: Singh, Rachana, et al.
Publicado: (2016)

ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma
por: Dacic, Sanja, et al.
Publicado: (2016)

374 Therapeutic Class Labeling of EGFR Companion Diagnostics (CDxs)
por: Chen, Joyce, et al.
Publicado: (2022)

Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
por: Krawczyk, Paweł, et al.
Publicado: (2021)

CT features and disease spread patterns in ROS1-rearranged lung adenocarcinomas: comparison with those of EGFR-mutant or ALK-rearranged lung adenocarcinomas
por: Woo, Jung Han, et al.
Publicado: (2020)

Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
por: Zhuang, Xibin, et al.
Publicado: (2019)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation
por: Miyanaga, Akihiko, et al.
Publicado: (2013)

Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
por: Huang, Ming-Hung, et al.
Publicado: (2022)

Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma
por: Xiao, Gang, et al.
Publicado: (2023)

FastProNGS: fast preprocessing of next-generation sequencing reads
por: Liu, Xiaoshuang, et al.
Publicado: (2019)

Role and clinical application of next-generation sequencing (NGS) for ovarian cancer
por: Lim, Myong Cheol, et al.
Publicado: (2017)

Targeted Next Generation Sequencing (NGS) to Diagnose Hereditary Hemolytic Anemias
por: Bharadwaj, Rishab, et al.
Publicado: (2020)

Fluorescent amplification for next generation sequencing (FA-NGS) library preparation
por: Chiniquy, Jennifer, et al.
Publicado: (2020)

Framework for Adoption of Next-Generation Sequencing (NGS) Globally in the Oncology Area
por: Horgan, Denis, et al.
Publicado: (2023)

Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET
por: Collier, T. Lee, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cqunppj9bs72p7pa02ogn1e84n